Competition & Peer Data API & CSV Delivery

Tiziana Life Sciences Ltd's Competitiveness

Name: Tiziana Life Sciences Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Tiziana Life Sciences Ltd (TLSA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

Competitors Tracked

129

Publicly traded peers

Peer Group Market Share

Share of combined sales, Q4 2025

Revenue Growth Y/Y

Peers: 10.89 %

Net Margin

Peers: 17.11 %

Key Findings: Tiziana Life Sciences Ltd vs Its Competitors

Scale: Tiziana Life Sciences Ltd ranks #289 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/TLSA/competitors                    

                        https://api.csimarket.com/api/v1/companies/TLSA/relationships                    

                        https://api.csimarket.com/api/v1/companies/TLSA/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Tiziana Life Sciences Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Tiziana Life Sciences Ltd	-	-	-	Yes
Competitors combined (127)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

TLSA Stock Performance relative to its Competitors

TLSA Competitors (weighted) Percent change over the selected range

Tiziana Life Sciences Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Competitors Combined
(46 of 109)

Similar-Size
(3 of 9)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Tiziana Life Sciences Ltd	-52.00 %	Underperformed
Competitors combined (109)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (9)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Tiziana Life Sciences Ltd's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

TLSA Stock Performance relative to Similar-Size Competitors

TLSA Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#	Competitor	TTM Share Price Return	vs U.S.A. 500
1	Ventyx Biosciences Inc	282.9%	Outperformed
2	Damora Therapeutics Inc	282.9%	Outperformed
3	180 Life Sciences Corp	282.9%	Outperformed
4	Prelude Therapeutics Inc	282.9%	Outperformed
5	Dianthus Therapeutics Inc	282.9%	Outperformed

Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Tiziana Life Sciences Ltd's best-performing tracked competitors requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API, trailing 12 months.

Tiziana Life Sciences Ltd's Comment on Competition and Industry Peers

Tiziana Pharmaceuticals operates in a competitive environment that includes large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies, and both public and private research organizations. Its lead asset, Foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), Amyotrophic Lateral Sclerosis (ALS), Multiple System Atrophy (MSA), and Alzheimer's Disease (AD). Other therapies in development for these conditions include a non-fully human monoclonal antibody with a different mechanism of action for na-SPMS, as well as various non-monoclonal antibody treatments targeting na-SPMS, ALS, MSA, and AD. Competitors and their strategic partners often possess significantly greater financial, technical, research and development, clinical, marketing, and manufacturing resources. Industry mergers and acquisitions may further consolidate these resources among fewer entities, which could reduce or eliminate Tiziana's commercial opportunities if competitors develop safer or more effective products.

Publicly Traded Peers of Tiziana Life Sciences Ltd

Revenue and income for trailing 12 months, in millions of $, except employees

Company	Market Cap	Revenues	Income	Employees
Tiziana Life Sciences Ltd	-	-	-18.43	16
Eli Lilly And Company	1,058,837.89	79,665.80	26,711.20	50,000
Johnson and Johnson	663,585.20	97,929.00	21,037.00	140,800
Beone Medicines Ltd	552,467.82	6,128.24	655.71	12,000
Abbvie Inc	471,581.88	64,386.00	6,316.00	57,000
Merck and Co Inc	367,264.30	66,569.00	3,170.00	75,000
SUBTOTAL	5,042,189.02	826,405.95	122,789.92	815,104

124 more competitors available

Sources: Tiziana Life Sciences Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on: September 29, 2026
Focus of this report: publicly traded companies. Ten additional tables on Tiziana Life Sciences Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Tiziana Life Sciences Ltd's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Sorafenib	Named by the company	85%	2022 to 2026	3
Foralumab	Named by the company	85%	2022 to 2026	3
Lenvatinib	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Tiziana Life Sciences Ltd's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Tiziana Life Sciences Ltd's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).

Company	Largest Segment	2nd Segment	3rd Segment
Eli Lilly And Company	Reportable 100.00 %	-	-
Johnson and Johnson	Oncology 29.26 %	Immunology 15.19 %	Surgery 10.48 %
Merck and Co Inc	Pharmaceutical segment 88.88 %	Animal Health segment 10.69 %	Corporate and Unallocated 0.43 %
Amgen Inc	Reportable 100.00 %	-	-
Pfizer Inc	U.S. Commercial Division 52.92 %	International Commercial Division 36.88 %	Global Hospital and Biosimilars Division 7.72 %

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

26 more Peers available

Tiziana Life Sciences Ltd's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $

Company	Market Cap	Revenue / Employee	Income / Employee
Tiziana Life Sciences Ltd	-	-	-1,151,938
Eli Lilly And Company	1,058,838	1,593,316	534,224
Johnson and Johnson	663,585	695,518	149,411
Beone Medicines Ltd	552,468	510,686	54,642
Abbvie Inc	471,582	1,129,579	110,807
Merck and Co Inc	367,264	887,587	42,267
PEERS TOTAL	5,042,189	1,013,886	150,669

124 more Peers available

Tiziana Life Sciences Ltd's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.

Company	Largest Market	2nd Market	3rd Market
Eli Lilly And Company	United States 61.21 %	Europe 18.42 %	Rest of world 14.00 %
Johnson and Johnson	United States 57.42 %	Europe 22.62 %	Asia-Pacific, Africa 14.78 %
Beone Medicines Ltd	United States 51.69 %	China 31.19 %	Europe 12.82 %
Merck and Co Inc	EMEA 23.60 %	Latin America 5.27 %	Asia Pacific 4.94 %
Gilead Sciences Inc	United States 70.78 %	Europe 16.44 %	Rest of World 12.77 %

Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

14 more Peers available

Tiziana Life Sciences Ltd's Position in Industry Market Structure

Market-capitalization share and concentration across all 498 companies in Tiziana Life Sciences Ltd's industry classification, broader than the peer set above. Market cap in millions of $.

Tiziana Life Sciences Ltd ranks #289 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).

Rank	Company	Market Cap	Industry Share
1	Eli Lilly And Company	1,058,838	19.26 %
2	Johnson and Johnson	663,585	12.07 %
3	Beone Medicines Ltd	552,468	10.05 %
4	Abbvie Inc	471,582	8.58 %
5	Merck and Co Inc	1,234	5.2%
6	Novartis Ag	1,234	5.2%
7	Abbott Laboratories	1,234	5.2%
8	Novo Nordisk A	1,234	5.2%
9	Pfizer Inc	1,234	5.2%
10	Vertex Pharmaceuticals Inc	1,234	5.2%
289	Tiziana Life Sciences Ltd	102	0.00 %

Full Industry Market Structure

Market cap and industry share for the rest of Tiziana Life Sciences Ltd's industry peers requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.

Tiziana Life Sciences Ltd's Same-Size Peers & Stock Performance

Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.

Rank	Company	Market Cap	TTM Return	3M Momentum	Beta	Sharpe (1Y)
284	Aardvark Therapeutics Inc	115	-58.96 %	-8.77 %	-	-0.02
285	Genelux Corporation	111	-41.81 %	-18.07 %	1.52	-0.29
286	Nrx Pharmaceuticals Inc	108	0.69 %	-24.29 %	1.24	0.38
287	Rafael Holdings Inc	103	42.28 %	-38.57 %	0.62	0.89
288	Medicinova Inc	1,234	12.3%	4.5%	1.10	0.80
289	Tiziana Life Sciences Ltd	102	-51.97 %	-24.10 %	0.70	-0.48
290	Milestone Pharmaceuticals Inc	1,234	12.3%	4.5%	1.10	0.80
291	Rallybio Corporation	1,234	12.3%	4.5%	1.10	0.80
292	Polaryx Therapeutics Inc	1,234	12.3%	4.5%	1.10	0.80
293	Verrica Pharmaceuticals Inc	1,234	12.3%	4.5%	1.10	0.80
294	Promis Neurosciences inc	1,234	12.3%	4.5%	1.10	0.80

Full Same-Size Peer Performance

Market cap, return, momentum, beta and Sharpe ratio for the rest of Tiziana Life Sciences Ltd's same-size peers requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.

Tiziana Life Sciences Ltd's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.

Metric	2023	2024	2025
Revenue Growth	-	-	-
Operating Margin	-	-	-
Return on Invested Capital	-160.84 %	-200.64 %	-3,333.12 %
P/E	-	-	-

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Tiziana Life Sciences Ltd's BCG Growth-Share Matrix

Relative market share (vs Tiziana Life Sciences Ltd's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.

Tiziana Life Sciences Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).

Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.

Tiziana Life Sciences Ltd's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.

Force	Assessment	Basis
Competitive Rivalry	High	Industry HHI of 823 (see Industry Market Structure & Concentration above)
Supplier Power	Not covered on this page	See Tiziana Life Sciences Ltd's dedicated suppliers page for concentration and dependency data
Buyer Power	Not covered on this page	See Tiziana Life Sciences Ltd's dedicated customers page for concentration and dependency data
Threat of Substitutes	-	No systematic data source for cross-product substitution exists in this system; not estimated

Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.

Tiziana Life Sciences Ltd's Industry Attractiveness & Competitive Strength

A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.

High Strength

Medium Strength

Low Strength

High Attractiveness

Invest / Grow

Selective

Medium Attractiveness

Invest / Grow

Selective

Harvest

Low Attractiveness

Selective

Harvest

Harvest / Divest Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.

Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.

Tiziana Life Sciences Ltd's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

No rule matched.

Weaknesses

Return on equity 35,470.5 points below the industry aggregate.
Underperforming the U.S.A. 500 over the trailing 12 months.
Low relative market share vs the industry leader (0.00x).
Piotroski F-Score of 2 or below, the standard financial-distress signal.

Opportunities

A meaningful share of tracked competitors (34.20 %) show financial-distress signals, a possible opening to gain share.

Threats

No rule matched.

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Tiziana Life Sciences Ltd's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months

Company	Quick Ratio	Working Capital	Debt / Equity	Asset Turnover
Tiziana Life Sciences Ltd	0.36	0.76	-	-
Eli Lilly And Company	0.20	1.48	1.59	0.66
Johnson and Johnson	0.37	1.05	0.60	0.49
Beone Medicines Ltd	2.30	3.16	0.23	0.73
Abbvie Inc	0.16	0.75	-	0.48
Merck and Co Inc	0.40	1.46	1.01	0.51

124 more Peers available

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Tiziana Life Sciences Ltd's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter

Company	Period	Revenue Y/Y	Revenue Q/Q	Income Y/Y	Income Q/Q
Tiziana Life Sciences Ltd	Q4 2025	-	-	-	-
Eli Lilly And Company	Q2 2026	+47.7 %	+16.0 %	+25.3 %	-4.1 %
Johnson and Johnson	Q2 2026	+6.6 %	+5.2 %	-0.1 %	+5.7 %
Beone Medicines Ltd	Q2 2026	+29.7 %	+12.7 %	+151.3 %	+4.2 %
Abbvie Inc	Q2 2026	+10.2 %	+13.3 %	+284.3 %	+418.8 %
Merck and Co Inc	Q2 2026	+5.1 %	+2.0 %	-	-
PEERS TOTAL		+9.0 %	+8.1 %	-6.0 %	+6.4 %

124 more Peers available

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Tiziana Life Sciences Ltd's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter

Company	Period	Costs Y/Y	Costs Q/Q	Capex Y/Y	Capex Q/Q
Tiziana Life Sciences Ltd	Q4 2025	-	-	+10.5 %	+10.5 %
Eli Lilly And Company	Q2 2026	+33.5 %	-8.6 %	+72.8 %	+26.1 %
Johnson and Johnson	Q2 2026	+5.5 %	-0.7 %	+26.7 %	+25.9 %
Beone Medicines Ltd	Q2 2026	+6.4 %	+4.5 %	-57.0 %	-32.6 %
Abbvie Inc	Q2 2026	-1.3 %	+1.7 %	+19.7 %	+21.5 %
Merck and Co Inc	Q2 2026	+23.6 %	+4.8 %	+16.9 %	-9.9 %

124 more Peers available

Tiziana Life Sciences Ltd's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover

Company	ROA	ROI	ROE	Receivables Turnover	Inventory Turnover
Tiziana Life Sciences Ltd	-	-	-	-	-
Eli Lilly And Company	21.97%	33.95%	92.54%	4.40	0.92
Johnson and Johnson	10.60%	13.30%	25.74%	5.47	2.17
Beone Medicines Ltd	7.82%	10.32%	14.24%	6.58	1.07
Abbvie Inc	4.68%	9.11%	-	4.99	3.66
Merck and Co Inc	2.42%	3.24%	6.59%	5.47	2.79

124 more Peers available

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Tiziana Life Sciences Ltd's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book

Company	P/E	Price / Sales	PEG	P/CF	Price / Book
Tiziana Life Sciences Ltd	-	-	-	-	-
Eli Lilly And Company	39.77	13.29	0.28	189.94	31.25
Johnson and Johnson	31.48	6.78	-	359.67	7.81
Beone Medicines Ltd	834.09	90.15	-	221.47	106.78
Abbvie Inc	75.22	7.32	1.50	4,623.35	-
Merck and Co Inc	119.91	5.52	-	-	8.75
PEERS AVERAGE	41.06	6.10		104.83	7.71

124 more Peers available

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.